Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Anti-CD45 Monoclonal Antibody AHN-12	NCIT_C74009	[A high affinity IgG1 monoclonal antibody with potential immunotherapeutic activity. Anti-CD45 monoclonal antibody AHN-12 recognizes CD45, a transmembrane protein tyrosine phosphatase that is expressed on the surface of normal and malignant hematopoietic cells.]
PDB BLAST	NCIT_C49050	[A protein profile search method designed to find distant homologs.]
Basic Local Alignment Search Tool	NCIT_C80132	[A sequence search method designed to find regions of similarity between biological sequences.]
Malignant Histiocyte-Like Cell	NCIT_C49051
Neoplastic Histiocyte-Like Cell	NCIT_C36961
Melanoma of the Conjunctiva cT1d TNM Finding v7	NCIT_C88646	[Melanoma of the bulbar conjunctiva greater than 3 quadrants. (from AJCC 7th Ed.)]
Teplizumab	NCIT_C88647
Melanoma of the Conjunctiva cT2a TNM Finding v7	NCIT_C88648	[Melanoma of the nonbulbar (palpebral, forniceal, but no caruncular) conjunctiva less than or equal to 1 quadrant. (from AJCC 7th Ed.)]
Melanoma of the Conjunctiva cT2b TNM Finding v7	NCIT_C88649	[Melanoma of the nonbulbar (palpebral, forniceal, but no caruncular) conjunctiva greater than 1 quadrant. (from AJCC 7th Ed.)]
Melanoma of the Conjunctiva cT(is) TNM Finding v7	NCIT_C88642	[Melanoma confined to the conjunctival epithelium. (from AJCC 7th Ed.)]
Melanoma of the Conjunctiva cT1a TNM Finding v7	NCIT_C88643	[Melanoma of the bulbar conjunctiva less than or equal to 1 quadrant. Note: Quadrants are defined by clock hour, starting at the limbus (e.g., 6, 9, 12, 3) extending from the central cornea, to and beyond the eyelid margins. This will bisect the caruncle. (from AJCC 7th Ed.)]
Melanoma of the Conjunctiva cT1b TNM Finding v7	NCIT_C88644	[Melanoma of the bulbar conjunctiva more than 1 but less than or equal to 2 quadrants. (from AJCC 7th Ed.)]
Melanoma of the Conjunctiva cT1c TNM Finding v7	NCIT_C88645	[Melanoma of the bulbar conjunctiva more than 2 but less than or equal to 3 quadrants. (from AJCC 7th Ed.)]
Copper Cu 64 Trastuzumab	NCIT_C74020	[A diagnostic radioimmunoconjugate comprised of the recombinant humanized monoclonal antibody trastuzumab conjugated with the positron-emitting radioisotope copper Cu 64. Copper Cu 64 trastuzumab binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2), allowing the detection of HER2 distribution using positron emission tomography (PET).]
Apricoxib	NCIT_C74021	[An orally bioavailable nonsteroidal anti-inflammatory agent (NSAID) with potential antiangiogenic and antineoplastic activities. Apricoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), thereby inhibiting the conversion of arachidonic acid into prostaglandins. Apricoxib-mediated inhibition of COX-2 may induce tumor cell apoptosis and inhibit tumor cell proliferation and tumor angiogenesis. COX-related metabolic pathways may represent crucial regulators of cellular proliferation and angiogenesis.]
COX-2 Inhibitor	NCIT_C80509	[A subgroup of non-steroidal anti-inflammatory drugs (NSAID) that specifically targets at cyclooxygenase 2, an enzyme involved in pain and inflammation.]
CXCR4 Inhibitor Q-122	NCIT_C74022	[An orally bioavailable inhibitor of CXCR4 with potential antineoplastic and antiviral activities. CXCR4 inhibitor MSX-122 binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor-1 (SDF-1) to the CXCR4 receptor and receptor activation, which may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the GPCR (G protein-coupled receptor) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; it is also a co-receptor for HIV entry into T cells.]
Unsolved	NCIT_C49049	[Lacking a solution, explanation, or answer.]
Autologous Dendritic Cell-Tumor Fusion Vaccine	NCIT_C74016	[A therapeutic cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous tumor cells with potential immunostimulatory and antineoplastic activities. Autologous dendritic cell-tumor fusion vaccine is generated in vitro by mixing DCs and irradiated tumor cells harvested from individual patients and treating them with polyethylene glycol (PEG) to produce DC-tumor cell fusion hybrid cells. Upon administration, autologous dendritic cell-tumor fusion vaccine may elicit antitumor humoral and cellular immune responses.]
CD3/CD28 Costimulated Autologous T-Cells	NCIT_C74017	[A population of T cells that have been sensitized to vaccine tumor antigen(s) in vivo; collected from the patient; co-stimulated with antibodies to the T-cell cell surface proteins CD3 and CD28 and expanded ex vivo; and then infused into the same patient. CD3, part of the T cell receptor complex, and CD28, a T-cell surface-associated co-stimulatory molecule, are both required for full T-cell activation. Adoptive transfer of CD3/CD28 costimulated vaccine-primed autologous T-cells may induce the production of interferon-gamma (IFN-gamma) and granulocyte-macrophage colony-stimulating factor (GM-CSF) and associated antitumor effects and a graft-versus-tumor (GVT) response.]